News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Biotech SynDevRx, Inc. Establishes Scientific Advisory Board with Key Anti-Angiogenesis and Oncology Leaders



1/8/2008 8:29:07 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SynDevRx™, Inc., a pre-clinical stage biotech company developing the potent anti-angiogenic compound Caplostatin™, announced today the formation of its Scientific Advisory Board. Chairing the SAB is Bruce R. Zetter Ph.D., Chief Scientific Officer of Children’s Hospital Boston and VP Research Harvard Medical School. Dr. Zetter brings a wealth of industry knowledge to SynDevRx.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES